Sandy Spring Bank’s AstraZeneca AZN Stock Holding History

Sandy Spring Bank’s Portfolio AZN Stock Details AZN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	$6.71M	Buy	45,658 +4,349	+11%	+$629K	0.28%	77
2024 Q4	$5.41M	Buy	41,309 +6,406	+18%	+$897K	0.22%	96
2024 Q3	$5.44M	Buy	34,903 +5,908	+20%	+$954K	0.22%	98
2024 Q2	$4.52M	Buy	28,995 +9,206	+47%	+$1.39M	0.2%	109
2024 Q1	$2.68M	Buy	19,789 +18,584	+1,542%	+$2.46M	0.12%	143
2023 Q4	$162K	Buy	1,205 +323	+37%	+$42K	0.01%	384
2023 Q3	$119K	Sell	882 -442	-33%	-$60.4K	0.01%	411
2023 Q2	$189K	Buy	1,324 +41	+3%	+$6.03K	0.01%	351
2023 Q1	$178K	Buy	1,283 +302	+31%	+$40.6K	0.01%	351
2022 Q4	$133K	Hold	981	–	–	0.01%	383
2022 Q3	$107K	Sell	981 -175	-15%	-$22.2K	0.01%	402
2022 Q2	$153K	Sell	1,156 -175	-13%	-$23K	0.01%	355
2022 Q1	$177K	Sell	1,331 -175	-12%	-$21K	0.01%	341
2021 Q4	$176K	Sell	1,506 -200	-12%	-$23.5K	0.01%	356
2021 Q3	$205K	Sell	1,706 -325	-16%	-$37.8K	0.01%	329
2021 Q2	$244K	Sell	2,031 -50	-2%	-$5.49K	0.01%	316
2021 Q1	$207K	Sell	2,081 -46	-2%	-$4.62K	0.01%	320
2020 Q4	$213K	Buy	2,127 +31	+1%	+$3.28K	0.01%	313
2020 Q3	$230K	Buy	2,096 +273	+15%	+$30.4K	0.02%	289
2020 Q2	$193K	Sell	1,823 -11	-0.6%	-$1.14K	0.01%	294
2020 Q1	$164K	Buy	1,834 +66	+4%	+$6.21K	0.01%	289
2019 Q4	$177K	Buy	1,768 +18	+1%	+$1.7K	0.01%	303
2019 Q3	$156K	Sell	1,750 -43	-2%	-$3.73K	0.01%	318
2019 Q2	$148K	Hold	1,793	–	–	0.01%	323
2019 Q1	$145K	Hold	1,793	–	–	0.01%	318
2018 Q4	$136K	Buy	1,793 +500	+39%	+$39K	0.01%	319
2018 Q3	$102K	Sell	1,293 -382	-23%	-$28.9K	0.01%	374
2018 Q2	$118K	Sell	1,675 -720	-30%	-$51.8K	0.01%	358
2018 Q1	$168K	Sell	2,395 -267	-10%	-$18.5K	0.01%	322
2017 Q4	$185K	Buy	2,662 +167	+7%	+$11.3K	0.02%	288
2017 Q3	$169K	Sell	2,495 -805	-24%	-$50.9K	0.02%	299
2017 Q2	$225K	Hold	3,300	–	–	0.02%	282
2017 Q1	$205K	Sell	3,300 -1,095	-25%	-$63.7K	0.02%	285
2016 Q4	$240K	Buy	4,395 +1,575	+56%	+$89.4K	0.02%	272
2016 Q3	$185K	Sell	2,820 -480	-15%	-$31.4K	0.02%	292
2016 Q2	$199K	Buy	3,300 +1,000	+43%	+$58.1K	0.02%	288
2016 Q1	$130K	Hold	2,300	–	–	0.01%	324
2015 Q4	$156K	Hold	2,300	–	–	0.02%	298
2015 Q3	$146K	Hold	2,300	–	–	0.02%	301
2015 Q2	$147K	Sell	2,300 -40	-2%	-$2.74K	0.02%	317
2015 Q1	$160K	Buy	2,340 +2,300	+5,750%	+$160K	0.02%	305
2014 Q4	$3K	Hold	40	–	–	﹤0.01%	745
2014 Q3	$3K	Hold	40	–	–	﹤0.01%	726
2014 Q2	$3K	Hold	40	–	–	﹤0.01%	732
2014 Q1	$3K	Sell	40 -356	-90%	-$23K	﹤0.01%	671
2013 Q4	$24K	Hold	396	–	–	﹤0.01%	455
2013 Q3	$21K	Hold	396	–	–	﹤0.01%	459
2013 Q2	$19K	Buy	+396	New	+$20.2K	﹤0.01%	452

Other funds holding AZN

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Sanders Capital West Palm Beach, Florida $83.9B AUM 37.89% 1-Year Est. Return

Sandy Spring Bank's AZN Position: Q1 2025 in Review

Sandy Spring Bank increased its AstraZeneca (AZN) stake by 11% in Q1 2025, buying an estimated $629K and bringing the position to 45,658 shares worth $6.71M. The position accounts for 0.28% of the portfolio, ranked #77.

Sandy Spring Bank first reported a position in AZN in Q2 2013 and has held it in 48 quarters since. 1,250 funds tracked by Wall St. Rank hold AZN as of Q1 2025.

Sandy Spring Bank held 45,658 shares of AstraZeneca worth $6.71M as of Q1 2025.
Sandy Spring Bank bought 4,349 AstraZeneca shares in Q1 2025, an estimated $629K.
AstraZeneca made up 0.28% of Sandy Spring Bank's portfolio in Q1 2025, its #77 holding.
Sandy Spring Bank first reported a position in AstraZeneca in Q2 2013 and has held it in 48 quarters since.
1,250 funds tracked by Wall St. Rank held AstraZeneca as of Q1 2025.

Based on Sandy Spring Bank's 13F filing for Q1 2025, filed 12 May 2025.